TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07396168: Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Sponsor: The Skin Center Dermatology Group · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$2,390,400

Rescue Site Savings

+$1,567,040

Unlock Full NCT07396168 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07396168 Rescue Dossier →